
Kevin Smith
Journalist
Bristol Myers Squibb's Zenbexus reduces risk of progression in multiple myeloma by 51%
The company has unveiled positive results from a Phase III study. The trial evaluated the efficacy of Zenbexus combined with Daratumumab and Dexamethasone (the ZDd triplet) in 800 patients with relapsed or refractory multiple myeloma (RRMM), at first relapse.
09 October 2026 at 01:13 am AEDT
Discover our authors
Romain Fournier
Chief Editor
Rachel Harp
Analyst
Antoine Alves d'Oliveira
Journalist
Alexandra Marill
Journalist
- Stock Market
- Our authors
- Kevin Smith


















